IL286248A - מעכבי tyk2 והשימוש בהם - Google Patents
מעכבי tyk2 והשימוש בהםInfo
- Publication number
- IL286248A IL286248A IL286248A IL28624821A IL286248A IL 286248 A IL286248 A IL 286248A IL 286248 A IL286248 A IL 286248A IL 28624821 A IL28624821 A IL 28624821A IL 286248 A IL286248 A IL 286248A
- Authority
- IL
- Israel
- Prior art keywords
- tyk2 inhibitors
- tyk2
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816698P | 2019-03-11 | 2019-03-11 | |
| US201962835376P | 2019-04-17 | 2019-04-17 | |
| US201962877741P | 2019-07-23 | 2019-07-23 | |
| US201962931119P | 2019-11-05 | 2019-11-05 | |
| PCT/US2020/021850 WO2020185755A1 (en) | 2019-03-11 | 2020-03-10 | Tyk2 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL286248A true IL286248A (he) | 2021-10-31 |
| IL286248B1 IL286248B1 (he) | 2025-08-01 |
| IL286248B2 IL286248B2 (he) | 2025-12-01 |
Family
ID=72427699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL286248A IL286248B2 (he) | 2019-03-11 | 2020-03-10 | מעכבי tyk2 והשימוש בהם |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220177486A1 (he) |
| EP (1) | EP3938369A4 (he) |
| JP (1) | JP7586829B2 (he) |
| KR (1) | KR102899985B1 (he) |
| CN (1) | CN113811534B (he) |
| AU (1) | AU2020239026B2 (he) |
| BR (1) | BR112021017996A2 (he) |
| CA (1) | CA3132632A1 (he) |
| IL (1) | IL286248B2 (he) |
| WO (1) | WO2020185755A1 (he) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| CA3134814A1 (en) * | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| WO2020233645A1 (zh) | 2019-05-21 | 2020-11-26 | 浙江海正药业股份有限公司 | 大环类衍生物、及其制备方法和用途 |
| JP7635228B2 (ja) | 2019-11-08 | 2025-02-25 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
| EP4214215A1 (en) * | 2020-09-16 | 2023-07-26 | Alumis Inc. | Tyk2 inhibitors and uses thereof |
| CN114591351B (zh) * | 2020-12-03 | 2023-12-05 | 成都科岭源医药技术有限公司 | 一种多环化合物及其制备方法和用途 |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| CA3245808A1 (en) * | 2022-03-16 | 2023-09-21 | Alumis Inc. | TYK2 INHIBITORS AND THEIR USES |
| CN119487037A (zh) * | 2022-03-16 | 2025-02-18 | 阿鲁米斯股份有限公司 | Tyk2抑制剂及其用途 |
| WO2023208244A1 (zh) * | 2022-04-29 | 2023-11-02 | 南京明德新药研发有限公司 | 大环类化合物及其应用 |
| JP2026512838A (ja) * | 2023-03-31 | 2026-04-21 | 北京普祺医薬科技股▲分▼有限公司 | 大環化合物、医薬組成物及びその使用 |
| WO2024222807A1 (en) * | 2023-04-27 | 2024-10-31 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Novel macrocyclic heteroaryl derivatives as kinase inhibitors |
| WO2025194074A1 (en) * | 2024-03-15 | 2025-09-18 | Neuron23, Inc. | Kinase modulators and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517882B2 (en) * | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| ES2702126T3 (es) * | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| ES2933350T3 (es) * | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| AU2016287568B2 (en) * | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| US10479793B2 (en) * | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| JOP20190092A1 (ar) * | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) * | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| SI3658557T1 (sl) | 2017-07-28 | 2024-10-30 | Takeda Pharmaceutical Company Limited | Zaviralci TYK2 in njihova uporaba |
| CN111182903A (zh) * | 2017-07-28 | 2020-05-19 | 特普医药公司 | 巨环化合物及其用途 |
| CN109053682B (zh) * | 2018-07-27 | 2020-10-27 | 东南大学 | 一种tdo小分子抑制剂衍生物及其抗肿瘤偶联物和制备方法 |
| CA3134814A1 (en) * | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| JP7635228B2 (ja) * | 2019-11-08 | 2025-02-25 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
-
2020
- 2020-03-10 CA CA3132632A patent/CA3132632A1/en active Pending
- 2020-03-10 US US17/438,329 patent/US20220177486A1/en not_active Abandoned
- 2020-03-10 EP EP20769748.3A patent/EP3938369A4/en active Pending
- 2020-03-10 BR BR112021017996A patent/BR112021017996A2/pt unknown
- 2020-03-10 AU AU2020239026A patent/AU2020239026B2/en active Active
- 2020-03-10 WO PCT/US2020/021850 patent/WO2020185755A1/en not_active Ceased
- 2020-03-10 IL IL286248A patent/IL286248B2/he unknown
- 2020-03-10 JP JP2021552136A patent/JP7586829B2/ja active Active
- 2020-03-10 CN CN202080034800.9A patent/CN113811534B/zh active Active
- 2020-03-10 KR KR1020217032541A patent/KR102899985B1/ko active Active
-
2025
- 2025-05-20 US US19/213,418 patent/US20250276977A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210141973A (ko) | 2021-11-23 |
| US20250276977A1 (en) | 2025-09-04 |
| CN113811534B (zh) | 2024-10-29 |
| US20220177486A1 (en) | 2022-06-09 |
| JP2022524974A (ja) | 2022-05-11 |
| CN113811534A (zh) | 2021-12-17 |
| IL286248B1 (he) | 2025-08-01 |
| IL286248B2 (he) | 2025-12-01 |
| WO2020185755A1 (en) | 2020-09-17 |
| JP7586829B2 (ja) | 2024-11-19 |
| KR102899985B1 (ko) | 2025-12-15 |
| AU2020239026B2 (en) | 2025-10-09 |
| CA3132632A1 (en) | 2020-09-17 |
| EP3938369A4 (en) | 2023-01-25 |
| EP3938369A1 (en) | 2022-01-19 |
| AU2020239026A1 (en) | 2021-09-23 |
| BR112021017996A2 (pt) | 2021-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282487A (he) | מעכבים מסוג tyk2 והשימוש בהם | |
| IL286248A (he) | מעכבי tyk2 והשימוש בהם | |
| IL282090A (he) | מעכבי tyk2 ושימושים בהם | |
| IL284799A (he) | מעכבי tyk2 ושימושים בהם | |
| IL285178A (he) | תירכובות והשימוש בהם | |
| SI3658557T1 (sl) | Zaviralci TYK2 in njihova uporaba | |
| DK3999506T3 (da) | Parp1-hæmmere | |
| IL283409A (he) | מעכבי tyk2 ושימושים בהם | |
| EP4003319A4 (en) | HDAC6 INHIBITORS AND THEIR USES | |
| IL287768A (he) | מעכבי kcnt1 ושיטות לשימוש | |
| IL287751A (he) | מעכבי kcnt1 ושיטות לשימוש | |
| IL283106A (he) | מעכבי erk ושימושים בהם | |
| EP3746071A4 (en) | GCN2 INHIBITORS AND THEIR USES | |
| EP3526222A4 (en) | TYK2 INHIBITORS AND THEIR USES | |
| EP3528816A4 (en) | TYK2 INHIBITORS AND USES THEREOF | |
| IL282350A (he) | מעכבים ברנני-rgmc ושימוש בהם | |
| IL288872A (he) | אימידאזופירימידינים כמעכבי eed והשימוש שלהם | |
| IL291191A (he) | מעכבי cdk והשימוש בהם כתרופות | |
| PL4031110T3 (pl) | Postacie dawkowania inhibitorów tyk2 | |
| IL291217A (he) | מעכבי usp30 ושימושים שלהם | |
| IL283782A (he) | אנלוסומים ושיטות לשימוש | |
| HUE063120T2 (hu) | LRRC33-inhibitorok és alkalmazásuk | |
| IL284514A (he) | תרכובות הלו-אלילאמין ושימוש בהן | |
| DK3796979T3 (da) | Mir-181-hæmmere og anvendelser deraf | |
| IL286485A (he) | מעכבי pi4-קיינאס ושיטות לשימוש בהן |